Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 5/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 2/20 | 0.48 |
| ▸ | CCND1 | P24385 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21837114 | 1.00 | MAPT (0.57) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL21837116 | 0.77 | MAPT (0.73) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL735125 | 0.75 | MAPT (1.00) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL29033817 | 0.74 | TGM2 (0.56) | MAPTALDH1A1TGM2 | |
| SCHEMBL20582267 | 0.74 | ALOX5 (0.51) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL22761105 | 0.74 | ALOX5 (0.51) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL23615723 | 0.74 | ALDH1A1 (0.56) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL22761054 | 0.74 | ALDH1A1 (0.56) | MAPTMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL22761266 | 0.69 | ALDH1A1 (0.52) | MAPTRAB9ANPC1TDP1POLB | |
| SCHEMBL23615790 | 0.68 | MAPT (0.59) | MAPTMEN1KMT2ARAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247982-B2 | NMDA receptor modulators, compositions comprising same and use of these compounds in the treatment of diseases involving the central nervous system | ADPUERIVITAM (FR) | 2022-02-15 | — | — | US | disclosed |
| US-11247982-B2 | NMDA receptor modulators, compositions comprising same and use of these compounds in the treatment of diseases involving the central nervous system | ADPUERIVITAM (FR) | 2022-02-15 | — | — | US | disclosed |
| EP-3634957-B1 | NMDA RECEPTOR MODULATORS, COMPOSITIONS COMPRISING SAME AND USE OF THESE COMPOUNDS IN THE TREATMENT OF DISEASES INVOLVING THE CENTRAL NERVOUS SYSTEM | ADPUERIVITAM (FR) | 2021-07-07 | — | — | EP | disclosed |
| EP-3634957-B1 | NMDA RECEPTOR MODULATORS, COMPOSITIONS COMPRISING SAME AND USE OF THESE COMPOUNDS IN THE TREATMENT OF DISEASES INVOLVING THE CENTRAL NERVOUS SYSTEM | ADPUERIVITAM (FR) | 2021-07-07 | — | — | EP | disclosed |
| US-20200385363-A1 | NMDA Receptor Modulators, Compositions Comprising Same And Use of These Compounds in the Treatment of Diseases Involving the Central Nervous System | ADPUERIVITAM (FR) | 2020-12-10 | — | — | US | disclosed |
| US-20200385363-A1 | NMDA Receptor Modulators, Compositions Comprising Same And Use of These Compounds in the Treatment of Diseases Involving the Central Nervous System | ADPUERIVITAM (FR) | 2020-12-10 | — | — | US | disclosed |
| EP-3634957-A1 | NMDA RECEPTOR MODULATORS, COMPOSITIONS COMPRISING SAME AND USE OF THESE COMPOUNDS IN THE TREATMENT OF DISEASES INVOLVING THE CENTRAL NERVOUS SYSTEM | Adpuerivitam (FR) | 2020-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11247982-B2 | NMDA receptor modulators, compositions comprising same and use of these compounds in the treatment of diseases involving the central nervous system | GRIN3A, GRIN1, GRIN2A | MAPT 69/4885MEN1 1274/4885KMT2A 549/4885 |
| US-20200385363-A1 | NMDA Receptor Modulators, Compositions Comprising Same And Use of These Compounds in the Treatment of Diseases Involving the Central Nervous System | GRIN1, GRIN2A, GRIN3A | MAPT 82/4885MEN1 788/4885KMT2A 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.